The Maharashtra Food and Drug Administration has cancelled the wholesale drug sale…

The record

The Maharashtra Food and Drug Administration has cancelled the wholesale drug sale licences of Cipla Pharma & Life Sciences Ltd.’s C&F warehouse at Wadki, Pune, after completing a fresh regulatory process in compliance with directions of the Bombay High Court.

pharmabiz.com5 Oct 2026

Maharashtra FDA has cancelled Cipla’s wholesale drug sale and distribution licence in Pune, citing regulatory and storage-related irregularities.

cnbctv18.com5 Oct 2026

The Maharashtra FDA has cancelled the drug sale licence of a Pune Cipla facility.

outlookbusiness.com3 Oct 2026

Cipla

₹1,335.50

▼ -0.63%

Close (EOD), as of 5 Oct 2026 · source

Cipla: results, dividends, orders, the full cited record →

More on Cipla

Cipla Ltd fell for a fifth straight session on October 5, 2026, quoting at Rs 1336, down 0.6% on the day.

6 Oct 2026 · 1 publisher

The Maharashtra Food and Drug Administration (FDA) cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding warehouse at Wadki in Pune.

3 Oct 2026 · 1 publisher

India's 10 largest pharmaceutical companies have maintained positive average volume growth through every month of 2026 so far, while smaller rivals have seen a more uneven performance.

20 Sep 2026 · 1 publisher

Invagen Pharmaceuticals, a subsidiary of Cipla, has partnered with Qilu Pharmaceutical for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda, for the United States.

7 Sep 2026 · 5 publishers

August saw at least four separate reports related to fake medicines, voluntary recalls, and alleged misbranding, impacting patient safety.

7 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.